Evidence map›Paper›PMID 34891045›Full record

ArticleNeuroImage. Clinical2022

Effective connectivity in subcortical visual structures in de novo Patients with Parkinson's Disease.

Emmanuelle Bellot, Louise Kauffmann, Véronique Coizet, Sara Meoni, Elena Moro, Michel Dojat

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in NeuroImage. Clinical, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02488395 (Superior Colliculus Activity in Parkinson Disease), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02488395 completednot on this map

Superior Colliculus Activity in Parkinson Disease: a Potential Marker? fMRI Brain Activation in Response to Visual Stimuli.

TypeobservationalSponsorInstitut National de la Santé Et de la Recherche Médicale, FranceRan2015 to 2018Enrolled23ConditionsParkinson's DiseaseArmsfMRI, Ophthalmologic evaluation, visual psychophysics test
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Emmanuelle BellotUniversity Grenoble Alpes, Inserm U1216, Centre Hospitalier Universitaire de Grenoble, Grenoble Institute of Neurosciences, Grenoble, France.
Louise KauffmannLaboratory of Psychology and Neurocognition, CNRS UMR 5105, Grenoble, France.
Véronique CoizetUniversity Grenoble Alpes, Inserm U1216, Centre Hospitalier Universitaire de Grenoble, Grenoble Institute of Neurosciences, Grenoble, France.
Sara MeoniUniversity Grenoble Alpes, Inserm U1216, Centre Hospitalier Universitaire de Grenoble, Grenoble Institute of Neurosciences, Grenoble, France; Laboratory of Psychology and Neurocognition, CNRS UMR 5105, Grenoble, France; Movement Disorders Unit, Division of Neurology, CHU Grenoble Alpes, Grenoble, France.
Elena MoroUniversity Grenoble Alpes, Inserm U1216, Centre Hospitalier Universitaire de Grenoble, Grenoble Institute of Neurosciences, Grenoble, France; Laboratory of Psychology and Neurocognition, CNRS UMR 5105, Grenoble, France.
Michel DojatUniversity Grenoble Alpes, Inserm U1216, Centre Hospitalier Universitaire de Grenoble, Grenoble Institute of Neurosciences, Grenoble, France. Electronic address: Michel.Dojat@inserm.fr.
Grenoble Institute of Neurosciences · FRCentre National de la Recherche Scientifique · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParkinson's disease (PD) manifests with the appearance of non-motor symptoms before motor symptoms onset. Among these, dysfunctioning visual structures have recently been reported to occur at early disease stages.

objectiveThis study addresses effective connectivity in the visual network of PD patients.

methodsUsing functional MRI and dynamic causal modeling analysis, we evaluated the connectivity between the superior colliculus, the lateral geniculate nucleus and the primary visual area V1 in de novo untreated PD patients (n = 22). A subset of the PD patients (n = 8) was longitudinally assessed two times at two months and at six months after starting dopaminergic treatment. Results were compared to those of age-matched healthy controls (n = 22).

resultsOur results indicate that the superior colliculus drives cerebral activity for luminance contrast processing both in healthy controls and untreated PD patients. The same effective connectivity was observed with neuromodulatory differences in terms of neuronal dynamic interactions. Our main findings were that the modulation induced by luminance contrast changes of the superior colliculus connectivity (self-connectivity and connectivity to the lateral geniculate nucleus) was inhibited in PD patients (effect of contrast: p = 0.79 and p = 0.77 respectively). The introduction of dopaminergic medication in a subset (n = 8) of the PD patients failed to restore the effective connectivity modulation observed in the healthy controls.

interpretationThe deficits in luminance contrast processing in PD was associated with a deficiency in connectivity adjustment from the superior colliculus to the lateral geniculate nucleus and to V1. No differences in cerebral blood flow were observed between controls and PD patients suggesting that the deficiency was at the neuronal level. Administration of a dopaminergic treatment over six months was not able to normalize the observed alterations in inter-regional coupling. These findings highlight the presence of early dysfunctions in primary visual areas, which might be used as early markers of the disease.

Indexed as

Parkinson DiseaseDopamineDopamine AgentsHumansMagnetic Resonance ImagingNeural PathwaysDopamineDopamine AgentsDynamic causal modelingfMRIHuman visionNeuroimagingSuperior colliculus

Identifiers

PMID34891045
PMCPMC8670854
OpenAlexW4200181623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.